BioSpace News Archive

Agile Therapeutics, Inc., a women’s healthcare company, provided an update on Twirla for 2022 and its commercial plan for 2023.

Travere Therapeutics, Inc. announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million.

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45, for the potential treatment of people living with Duchenne who are exon 45 skipping amenable.

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3 of 2023.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers show rapid, sustained and >97 percent suppression of the alternative pathway (AP) of the complement system 24 hours following a single 110 mg dose.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of its Investigational New Drug (IND) application to initiate clinical testing of TN-201.

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference.

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022.

Mednow Inc. (“ Mednow '' or the “ Company ”) (TSXV:MNOW), Canada’s on-demand virtual pharmacy, is pleased to announce the Company will be hosting its quarterly conference call on Wednesday January 18, 2023 at 8:30am EST.

Schrödinge , Inc. today provided an update on its progress across the business and announced its strategic priorities for 2023.